GlassScriptPhysician profile
Richard Bowles
NPI 1891059283
$4,506.30
in general payments reported to CMS, 2019-2025
32 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $48.26 · 2021: $82.00 · 2022: $604 · 2023: $970 · 2024: $1,249 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,517.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $643.56 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.69 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $445.59 | 2019-2025 | |
| Novo Nordisk INC | $416.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $359.28 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $357.76 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $224.81 | 2019-2025 | Gardasil 9, Gardasil, Capvaxive |
| Sanofi-Aventis U.S. LLC | $160.01 | 2022-2025 | |
| Dexcom, INC. | $153.19 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $143.18 | 2019-2024 | Ubrelvy |
| Exact Sciences Corporation | $132.23 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $127.69 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $110.98 | 2019-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $92.38 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $73.52 | 2024-2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $73.02 | 2022-2025 | Keveyis |
| Astellas Pharma US INC | $68.12 | 2025 | Veozah |
| Amgen INC. | $60.83 | 2023-2025 | Evenity, Prolia |
| Sanofi Pasteur INC. | $47.97 | 2019-2023 | |
| Eisai INC. | $33.86 | 2025 | |
| Zyla Life Sciences, INC. | $30.81 | 2019 | |
| Lundbeck LLC | $27.97 | 2025 | Vyepti |
| Idorsia Pharmaceuticals US INC | $25.68 | 2022-2024 | Quviviq |
| Seqirus USA INC | $22.58 | 2025 | Flucelvax, Fluad |
| Corcept Therapeutics | $22.36 | 2024 | Korlym |
| Optinose US, INC. | $20.16 | 2024 | |
| Janssen Pharmaceuticals, INC | $19.95 | 2022 | |
| Dynavax Technologies Corporation | $19.74 | 2023 | Heplisav-B |
| Axsome Therapeutics, INC. | $18.84 | 2025 | Auvelity |
| Horizon Therapeutics Plc | $15.90 | 2019 | |
| Genentech USA, INC. | $13.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.